Overview: A Major Strategic Pivot
GE HealthCare (Nasdaq: GEHC) is reshaping its business in a significant way. On April 29, 2026, the Chicago-based healthcare technology giant announced plans to merge its two largest operating segments while simultaneously cutting its profit outlook for the full year. Tariffs, supply chain pressures, and rising input costs are driving these sweeping changes. Investors responded swiftly — shares fell nearly 13% in morning trading, touching a fresh 52-week low.
Q1 2026 Earnings: Revenue Up, Profits Under Pressure
Strong Revenue, Missed Earnings Target
GE HealthCare posted mixed first-quarter results. Total Q1 revenue rose 7.4% year over year to $5.13 billion, surpassing Wall Street’s estimate of $5.04 billion. Furthermore, organic revenue growth came in at nearly 3%. However, the company missed on the bottom line. Adjusted earnings per share stood at 99 cents, falling short of the consensus estimate of $1.05.
Segment-by-Segment Performance
- Imaging sales climbed 3.8% to $2.14 billion, supported by volume gains despite tariff headwinds.
- Advanced Visualization Solutions (AVS) revenue reached $1.24 billion, up 4.4%, aided by volume and contract settlements.
- Patient Care Solutions (PCS) saw revenues decline 8.1% to $753 million, primarily because large monitoring installations shifted toward the second half of the year.
- The company’s total backlog stands at a robust $21.8 billion, with a book-to-bill ratio of 1.07x.
The New Advanced Imaging Solutions Segment
A $14.6 Billion Imaging Powerhouse
The most consequential structural change is the creation of Advanced Imaging Solutions (AIS) — a new segment formed by merging Imaging and Advanced Visualization Solutions. Together, these two units form a $14.6 billion segment, making AIS one of the largest imaging businesses in the world.
What AIS Includes
AIS brings together an AI-enabled portfolio spanning:
- MR and CT systems
- Molecular Imaging and Women’s Health
- X-ray and Ultrasound
- Image-guided solutions and enterprise imaging
According to GE HealthCare, this combination creates a more “focused and connected end-to-end imaging ecosystem” spanning diagnosis, intervention, and follow-up care across disease states. Consequently, workflows become more seamless, decision-making faster, and procedural support more precise.
Segments That Remain Separate
Meanwhile, Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS) will continue to operate as independent segments. GE HealthCare expects to file recast financial results reflecting the new structure by its Q2 2026 earnings release.
Executive Shakeup: Key Leadership Changes
New Leaders Step In
Phil Rackliffe has been appointed President and CEO of the newly formed Advanced Imaging Solutions segment. Rackliffe previously served as President and CEO of AVS (2024–2026) and led Image Guided Therapies before that. He spearheaded the launches of Vivid Pioneer — GE HealthCare’s most advanced AI-powered cardiovascular ultrasound — and Allia™ Moveo, a compact, cable-free interventional system.
Additionally, Catherine Estrampes has been named Chief Commercial and Growth Officer. She will lead Global Markets, a newly created region covering every market except China.
A Departure at the Top
Roland Rott, who served as President and CEO of Imaging since 2024, is leaving the company to “pursue external opportunities.” CEO Peter Arduini thanked Rott for “significant contributions over the past 15 years.”
Why GE HealthCare Is Reducing Its 2026 Profit Outlook
Inflation and Tariffs Are the Culprits
GE HealthCare now expects adjusted EPS of $4.80–$5.00 for full-year 2026, down from prior guidance of $4.95–$5.15. This revision also falls below the analyst consensus of $5.07. Additionally, the company trimmed its free cash flow outlook from approximately $1.7 billion to $1.6 billion.
CEO Arduini explained the rationale: “Given these dynamics, we are taking a prudent approach and reducing our profit outlook.” He added that the company aims to offset more than half of the inflation impact through price increases and cost-cutting measures. Notably, GE HealthCare reiterated its organic revenue growth guidance of 3%–4% for 2026, signaling continued confidence in its top-line trajectory.
Wall Street Reacts to the Announcement
Downgrades and Target Cuts
The market reaction was sharp. Goldman Sachs downgraded GE HealthCare stock, with analyst David Roman citing rising input costs and tariff-driven uncertainty as overshadowing stronger business fundamentals. The firm lowered its valuation multiple from 14x to 12x forward earnings. Similarly, Mizuho cut its price target from $90 to $80, while Evercore ISI reduced its target from $85 to $80. However, both firms maintained positive ratings, reflecting confidence in the company’s longer-term pipeline and new product execution.
What Comes Next for GEHC
GE HealthCare is clearly playing a long game. The AIS merger signals a strategic bet on integrated imaging as the core engine of future growth. Paired with its AI-powered product portfolio and a strong $21.8 billion backlog, the company has tangible assets to weather near-term macro pressures. Therefore, while the 2026 outlook has been trimmed, the structural moves position GEHC for a stronger competitive stance heading into 2027 and beyond.
